Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
作者信息
Teitelbaum Steven L, Seton Margaret P, Saag Kenneth G
机构信息
Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri 63110, USA.
出版信息
Arthritis Rheum. 2011 Feb;63(2):325-8. doi: 10.1002/art.30135.
Abstract
摘要
相似文献
1
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
Arthritis Rheum. 2011 Feb;63(2):325-8. doi: 10.1002/art.30135.
2
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
J Bone Miner Metab. 2019 May;37(3):554-562. doi: 10.1007/s00774-018-0955-7. Epub 2018 Sep 5.
3
Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Int J Rheum Dis. 2018 Mar;21(3):647-655. doi: 10.1111/1756-185X.13206. Epub 2017 Nov 3.
4
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Arch Osteoporos. 2018 Jun 13;13(1):67. doi: 10.1007/s11657-018-0451-7.
5
Glucocorticoid-induced osteoporosis and osteonecrosis.
Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611. doi: 10.1016/j.ecl.2012.04.004. Epub 2012 May 23.
6
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Reumatismo. 2017 May 22;69(1):30-39. doi: 10.4081/reumatismo.2017.922.
7
Advances in treatment of glucocorticoid-induced osteoporosis.
Curr Opin Endocrinol Diabetes Obes. 2017 Dec;24(6):411-417. doi: 10.1097/MED.0000000000000368.
8
[New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Clin Calcium. 2009 Jan;19(1):44-53.
9
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6.
10
Glucocorticoid-induced Osteoporosis.
Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24.
引用本文的文献
1
Prolonged Impact of Bisphosphonates and Glucocorticoids on Bone Mechanical Properties.
Pharmaceuticals (Basel). 2025 Jan 26;18(2):164. doi: 10.3390/ph18020164.
2
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.
Arch Osteoporos. 2025 Feb 24;20(1):31. doi: 10.1007/s11657-025-01512-9.
3
GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE.
Trans Am Clin Climatol Assoc. 2023;133:69-80.
4
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.
Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019.
5
Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage.
Int J Mol Sci. 2019 Aug 19;20(16):4038. doi: 10.3390/ijms20164038.
6
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.
Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6.
7
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
J Bone Miner Metab. 2019 Sep;37(5):805-814. doi: 10.1007/s00774-019-00989-y. Epub 2019 Jan 31.
8
Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
Osteoporos Int. 2017 Nov;28(11):3251-3259. doi: 10.1007/s00198-017-4169-y. Epub 2017 Jul 27.
9
High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
Osteoporos Int. 2017 Aug;28(8):2367-2376. doi: 10.1007/s00198-017-4038-8. Epub 2017 Apr 13.
10
One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy.
RMD Open. 2016 Sep 12;2(2):e000313. doi: 10.1136/rmdopen-2016-000313. eCollection 2016.
本文引用的文献
1
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.
J Bone Miner Res. 2010 Nov;25(11):2267-94. doi: 10.1002/jbmr.253.
2
Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation.
J Bone Miner Res. 2011 Mar;26(3):657-65. doi: 10.1002/jbmr.241.
3
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Bone. 2010 Apr;46(4):929-34. doi: 10.1016/j.bone.2009.12.021. Epub 2010 Jan 6.
4
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
J Rheumatol. 2010 Jan;37(1):141-8. doi: 10.3899/jrheum.090411. Epub 2009 Nov 16.
5
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.
6
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
Ann Rheum Dis. 2010 May;69(5):872-5. doi: 10.1136/ard.2009.112920. Epub 2009 Sep 3.
7
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.
8
Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
Calcif Tissue Int. 2009 Jul;85(1):37-44. doi: 10.1007/s00223-009-9263-5. Epub 2009 Jun 23.
9
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.
10
Bisphosphonates: mechanism of action and role in clinical practice.
Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
Zotero 插件